vWF Inhibitors
1 drugsAbout vWF
Von Willebrand factor (vWF) is a protein crucial for blood coagulation, specifically platelet adhesion and aggregation at vascular injury sites. Its role in hemostasis makes it a target for therapeutic intervention in bleeding disorders.
Currently, there is no genetic evidence available linking vWF to specific diseases. Targeting vWF offers a pathway to modulate blood clotting processes.
CABLIVI is the only FDA-approved drug that interacts with vWF. It is a biologic (other) modality, representing a unique area of drug development focused on coagulation-related conditions.
Top vWF Drugs
ABLYNX NV is the only company with an approved drug targeting vWF.
The market is not competitive, so new entrants may face fewer direct rivals but must overcome ABLYNX's established position.
vWF Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets vWF, using biologic (other) modality.
Explore opportunities for small molecule or antibody-based vWF targeting to diversify the therapeutic options.
vWF Clinical Trials 6 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on vWF. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
| Phase 2 | 2 | 1 | 1 | 0 | 50% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
vWF Drug Approval Timeline (2019 - 2019)
The first and only drug, CABLIVI, was approved in 2019.
The recent approval and lack of subsequent drugs suggest an unsaturated market with potential for further innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on vWF. A trial counts if an approved drug acting on vWF is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.